Home / BusinessBusinessMarketWatchBusinessMarketWatch·Aug 5, 2026·1 min readLilly’s revenue soars 48%, driven by demand of its GLP-1sIts sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.View original source — MarketWatch ↗ShareCopy linkShare on XShare on FacebookRelated storiesBusinessCNBCBusinessAug 5, 2026 · 1 minWe're adding to our position in a chipmaker as the AI trade regains its footingCNBCBusinessBloombergBusinessAug 5, 2026 · 1 minUS Companies Added Fewer Jobs Than Expected in July: ADPBloombergBusinessMarketWatchBusinessAug 5, 2026 · 1 minThe government owns some of the same stocks you do. Here’s why that is risky.MarketWatchBusinessMarketWatchBusinessAug 5, 2026 · 1 minADP says businesses add the fewer new jobs in six monthsMarketWatch
BusinessCNBCBusinessAug 5, 2026 · 1 minWe're adding to our position in a chipmaker as the AI trade regains its footingCNBC
BusinessBloombergBusinessAug 5, 2026 · 1 minUS Companies Added Fewer Jobs Than Expected in July: ADPBloomberg
BusinessMarketWatchBusinessAug 5, 2026 · 1 minThe government owns some of the same stocks you do. Here’s why that is risky.MarketWatch
BusinessMarketWatchBusinessAug 5, 2026 · 1 minADP says businesses add the fewer new jobs in six monthsMarketWatch